5-(4-phenoxybenzylidene)-2-thioxodihydropyrimidine-4,6-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(4-phenoxybenzylidene)-2-thioxodihydropyrimidine-4,6-dione
• 英文别名: 5-[(4-Phenoxyphenyl)methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
• 化学式: C₁₇H₁₂N₂O₃S
• 分子量: 324.36
• InChiKey: YIYCGYXIDCCILN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Barbituric acid analogs as therapeutic agents
  申请人：——

  公开号：US20030229108A1

  公开（公告）日：2003-12-11

  This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1&agr; and p300) and thereby inhibit angiogenesis, tumorigensis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HIF-1 activity, and to inhibit angiogensis, tumorigensis, and proliferative conditions, such as cancer.

  这项发明涉及活性巴比妥酸类似物，其抑制HIF-1活性（例如，HIF-1α与p300之间的相互作用），从而抑制血管生成、肿瘤发生和增生性疾病，如癌症。本发明还涉及包括这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制HIF-1活性，以及抑制血管生成、肿瘤发生和增生性疾病，如癌症。
• BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS
  申请人：Novuspharma S.p.A.

  公开号：EP1305026A2

  公开（公告）日：2003-05-02
• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：IRM LLC

  公开号：EP2057146A1

  公开（公告）日：2009-05-13
• [EN] BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS<br/>[FR] ANALOGUES DE L'ACIDE BARBITURIQUE UTILISES COMME AGENTS THERAPEUTIQUES
  申请人：PROLIFIX LTD

  公开号：WO2001093841A2

  公开（公告）日：2001-12-13

  This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1α and p300) and thereby inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HIF-1 activity, and to inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer.
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILISÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：IRM LLC

  公开号：WO2008042639A1

  公开（公告）日：2008-04-10

  [EN] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.
  [FR] La présente invention concerne une nouvelle classe de composés, des compositions pharmaceutiques contenant de tels composés et des procédés d'utilisation desdits composés pour traiter ou prévenir des maladies ou des troubles associés à une activité kinase anormale ou déréglée, particulièrement les maladies ou les troubles qui impliquent l'activation anormale des kinases Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 et TrkB.